The oral therapy of Novo Nordisk with a weight loss of over 13% in 12 weeks has been applied for clinical trials in China. According to the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration of China, the clinical trial application for Novo Nordisk's Class 1 new drug, amycretin tablets, has been accepted. Public information shows that this is a long-acting co agonist developed by Novo Nordisk for oral GLP-1 receptor and amylin receptor, serving as a new generation of weight loss therapy.